New COVID booster for teens shows promise in trial

NCT ID NCT06234956

Completed ⭐️ VACCINE ⭐️ Sponsor: Hipra Scientific, S.L.U Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a booster shot called BIMERVAX in 242 teenagers aged 12 to 17 who had already received a different COVID-19 vaccine. The goal was to see if it safely boosts their immune protection against the virus, including the Omicron variant. Participants were followed for 12 months to monitor side effects and immune response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV-2 INFECTION

Contacts and locations

Locations

CAP Centelles

Centelles, Barcelona, 08540, Spain
CAP Peralada

Peralada, Girona, 17491, Spain
Hospital HM Montepríncipe

Boadilla del Monte, Madrid, 28660, Spain
Hospital HM Puerta del Sur

Móstoles, Madrid, 28938, Spain
Hospital Josep Trueta

Girona, Girona, 17007, Spain
Hospital La Paz

Madrid, Madrid, 28046, Spain
Hospital Vall Hebron

Barcelona, Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.